Cargando…

The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study

BACKGROUND: Survey-based studies are frequently used to describe the economic impact of multiple sclerosis (MS). However, there is no validated health resource survey available, preventing comparison of study results and meaningful conclusions regarding the efficiency of long-term treatments. OBJECT...

Descripción completa

Detalles Bibliográficos
Autores principales: Ness, Nils-Henning, Haase, Rocco, Kern, Raimar, Schriefer, Dirk, Ettle, Benjamin, Cornelissen, Christian, Akguen, Katja, Ziemssen, Tjalf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109610/
https://www.ncbi.nlm.nih.gov/pubmed/32181745
http://dx.doi.org/10.2196/17921
_version_ 1783512990335631360
author Ness, Nils-Henning
Haase, Rocco
Kern, Raimar
Schriefer, Dirk
Ettle, Benjamin
Cornelissen, Christian
Akguen, Katja
Ziemssen, Tjalf
author_facet Ness, Nils-Henning
Haase, Rocco
Kern, Raimar
Schriefer, Dirk
Ettle, Benjamin
Cornelissen, Christian
Akguen, Katja
Ziemssen, Tjalf
author_sort Ness, Nils-Henning
collection PubMed
description BACKGROUND: Survey-based studies are frequently used to describe the economic impact of multiple sclerosis (MS). However, there is no validated health resource survey available, preventing comparison of study results and meaningful conclusions regarding the efficiency of long-term treatments. OBJECTIVE: The aim of this study was to develop and validate a tablet- and paper-based MS health resource utilization survey. METHODS: We developed and validated the Multiple Sclerosis Health Resource Utilization Survey (MS-HRS), consisting of 24 cost items for paper and tablet users. Data for validation came from two large German observational studies. Survey practicability was assessed according to the response rate. Reliability was described using test-retest reliability as well as Guttman lambda. Construct validity was assessed as convergent and discriminant validity via correlations with associated patient-reported outcomes and known-group analyses. RESULTS: In total, 2207 out of 2388 (response rate: 92.4%) patients completed the survey and were included to determine psychometric properties. The test-retest reliability had an intraclass correlation coefficient of 0.828 over a course of 3 months. Convergent validity analyses showed that total costs correlated positively with increased disability (r=0.411, P<.001). For discriminant validity, correlations of total costs with the Treatment Satisfaction Questionnaire for Medication ranged from −0.006 (convenience) to −0.216 (effectiveness). The mean annual cost was €28,203 (SD €14,808) (US $39,203; SD US $20,583) with disease-modifying therapies. CONCLUSIONS: The MS-HRS is a multilingual, reliable, valid, electronically available, and easy-to-administer questionnaire providing a holistic cross-sectional and longitudinal assessment of resource utilization in patients with MS.
format Online
Article
Text
id pubmed-7109610
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher JMIR Publications
record_format MEDLINE/PubMed
spelling pubmed-71096102020-04-09 The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study Ness, Nils-Henning Haase, Rocco Kern, Raimar Schriefer, Dirk Ettle, Benjamin Cornelissen, Christian Akguen, Katja Ziemssen, Tjalf J Med Internet Res Original Paper BACKGROUND: Survey-based studies are frequently used to describe the economic impact of multiple sclerosis (MS). However, there is no validated health resource survey available, preventing comparison of study results and meaningful conclusions regarding the efficiency of long-term treatments. OBJECTIVE: The aim of this study was to develop and validate a tablet- and paper-based MS health resource utilization survey. METHODS: We developed and validated the Multiple Sclerosis Health Resource Utilization Survey (MS-HRS), consisting of 24 cost items for paper and tablet users. Data for validation came from two large German observational studies. Survey practicability was assessed according to the response rate. Reliability was described using test-retest reliability as well as Guttman lambda. Construct validity was assessed as convergent and discriminant validity via correlations with associated patient-reported outcomes and known-group analyses. RESULTS: In total, 2207 out of 2388 (response rate: 92.4%) patients completed the survey and were included to determine psychometric properties. The test-retest reliability had an intraclass correlation coefficient of 0.828 over a course of 3 months. Convergent validity analyses showed that total costs correlated positively with increased disability (r=0.411, P<.001). For discriminant validity, correlations of total costs with the Treatment Satisfaction Questionnaire for Medication ranged from −0.006 (convenience) to −0.216 (effectiveness). The mean annual cost was €28,203 (SD €14,808) (US $39,203; SD US $20,583) with disease-modifying therapies. CONCLUSIONS: The MS-HRS is a multilingual, reliable, valid, electronically available, and easy-to-administer questionnaire providing a holistic cross-sectional and longitudinal assessment of resource utilization in patients with MS. JMIR Publications 2020-03-17 /pmc/articles/PMC7109610/ /pubmed/32181745 http://dx.doi.org/10.2196/17921 Text en ©Nils-Henning Ness, Rocco Haase, Raimar Kern, Dirk Schriefer, Benjamin Ettle, Christian Cornelissen, Katja Akguen, Tjalf Ziemssen. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 17.03.2020. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research, is properly cited. The complete bibliographic information, a link to the original publication on http://www.jmir.org/, as well as this copyright and license information must be included.
spellingShingle Original Paper
Ness, Nils-Henning
Haase, Rocco
Kern, Raimar
Schriefer, Dirk
Ettle, Benjamin
Cornelissen, Christian
Akguen, Katja
Ziemssen, Tjalf
The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study
title The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study
title_full The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study
title_fullStr The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study
title_full_unstemmed The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study
title_short The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study
title_sort multiple sclerosis health resource utilization survey (ms-hrs): development and validation study
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109610/
https://www.ncbi.nlm.nih.gov/pubmed/32181745
http://dx.doi.org/10.2196/17921
work_keys_str_mv AT nessnilshenning themultiplesclerosishealthresourceutilizationsurveymshrsdevelopmentandvalidationstudy
AT haaserocco themultiplesclerosishealthresourceutilizationsurveymshrsdevelopmentandvalidationstudy
AT kernraimar themultiplesclerosishealthresourceutilizationsurveymshrsdevelopmentandvalidationstudy
AT schrieferdirk themultiplesclerosishealthresourceutilizationsurveymshrsdevelopmentandvalidationstudy
AT ettlebenjamin themultiplesclerosishealthresourceutilizationsurveymshrsdevelopmentandvalidationstudy
AT cornelissenchristian themultiplesclerosishealthresourceutilizationsurveymshrsdevelopmentandvalidationstudy
AT akguenkatja themultiplesclerosishealthresourceutilizationsurveymshrsdevelopmentandvalidationstudy
AT ziemssentjalf themultiplesclerosishealthresourceutilizationsurveymshrsdevelopmentandvalidationstudy
AT nessnilshenning multiplesclerosishealthresourceutilizationsurveymshrsdevelopmentandvalidationstudy
AT haaserocco multiplesclerosishealthresourceutilizationsurveymshrsdevelopmentandvalidationstudy
AT kernraimar multiplesclerosishealthresourceutilizationsurveymshrsdevelopmentandvalidationstudy
AT schrieferdirk multiplesclerosishealthresourceutilizationsurveymshrsdevelopmentandvalidationstudy
AT ettlebenjamin multiplesclerosishealthresourceutilizationsurveymshrsdevelopmentandvalidationstudy
AT cornelissenchristian multiplesclerosishealthresourceutilizationsurveymshrsdevelopmentandvalidationstudy
AT akguenkatja multiplesclerosishealthresourceutilizationsurveymshrsdevelopmentandvalidationstudy
AT ziemssentjalf multiplesclerosishealthresourceutilizationsurveymshrsdevelopmentandvalidationstudy